Skip to content
OpenCapital
Get started

Lineage Cell Therapeutics LCTX Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$2.8MBeat by $876.1KDiluted EPS-$0.01Beat by $0.01
Revenue estimate$1.9M
EPS estimate-$0.02

Next report

Aug 11, 2026 (In 3 weeks)
Revenue estimate$1.8M
EPS estimate-$0.03

Versus estimates

Revenue

Q1 2026$1.7MMiss by $1.9MQ4 2025$6.6MBeat by $4.6MQ3 2025$3.7MBeat by $1.7M
Q2 2025$2.8MBeat by $876.1K
Q1 2025$1.5MMiss by $222.3KQ4 2024$2.9MBeat by $1.5M

Diluted EPS

Q1 2026-$0.03Miss by $0.01Q4 2025$0.00Beat by $0.05Q3 2025-$0.13Miss by $0.11
Q2 2025-$0.01Beat by $0.01
Q1 2025-$0.02In lineQ4 2024-$0.01Beat by $0.03

Ask the moment Lineage Cell Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Lineage Cell Therapeutics report Q2 2025 earnings?
Lineage Cell Therapeutics (LCTX) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Lineage Cell Therapeutics's Q2 2025 revenue and EPS?
Lineage Cell Therapeutics reported revenue of $2.8M and diluted EPS of $-0.01 for Q2 2025.
Did Lineage Cell Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $1.9M by $876.1K. EPS beat the consensus estimate of $-0.02 by $0.01.
How did Lineage Cell Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 96.4% from $1.4M a year earlier and diluted EPS grew 66.7% from $-0.03.
Where can I find Lineage Cell Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107333) directly on SEC EDGAR. The filing index links above go to sec.gov.